This new patent follows research whcih showed that pretreatment and early therapy of experimental autoimmune myocarditis with a compound developed by Cel-Sci resulted in significant reduction in heart enlargement and disease associated histopathological changes in mice. The compound used was derived from Cel-Sci’s patented Ligand Epitope Antigen Presentation System (LEAPS) platform technology.
Such findings could potentially lead to the development of a treatment for autoimmune myocarditis, a life threatening heart disease, which is characterized by an enlarged and weakened heart. Myocarditis is a precursor to dilated cardiomyopathy, a condition leading to a form of chronic heart failure characterized by an inflamed heart.
The protection against experimentally induced myocarditis was statistically significant for both pretreatment and early therapy with the LEAPS compound in scientific investigations. The response was antigen-specific and was associated with an increase in IL-13 in both the sera and heart tissue and of IL-1 alpha in the sera of the protected mice.